Results 331 to 340 of about 840,802 (388)

A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. [PDF]

Theranostics
Kim RK, Heo CK, Choi MJ, Kahm YJ, Kim MK, Lee M, Lee JY, Park H, Jung U, Shin BC, Kim BJ, Kim SC, Cho EW, Ryu CJ, Kim IG.   +14 more
europepmc   +1 more source

Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade. [PDF]

J Exp Clin Cancer Res
Wang C, Ai Z, Wang Y, Luo M, Wu T, Wang D, Liu X, Lv J, Guo X, Wang Z, Sun Q, Liao X, Wu L.   +12 more
europepmc   +1 more source

Manganese-engineered Lactobacillus Reuteri with enhanced antitumor and immunomodulatory activities for colorectal cancer prevention and treatment. [PDF]

Nat Commun
Cao P, Li Q, Li Y, Guo H, Wei C, Xu R, Ouyang C, Chen W, Wang L, Wang Z.   +9 more
europepmc   +1 more source

Correction: Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer. [PDF]

Sci Rep
Ren W, Liu J, Zhao R, Zhao F, Zhang Y, Mu J, Zhu T.   +6 more
europepmc   +1 more source

L-Tetrahydropalmatine synergizes cytotoxic CD8⁺ T mediated antitumor and ferroptosis in gastric cancer. [PDF]

Cell Death Discov
Zhou L, Wei Y, Lin K, Lu Y.
europepmc   +1 more source

Antitumor antibiotics.

Postepy higieny i medycyny doswiadczalnej, 1974
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dihydrochalcones as Antitumor Agents

Current Medicinal Chemistry, 2022
Abstract: Dihydrochalcones are a class of secondary metabolites, possessing several biological properties such as antitumor, antioxidant, antibacterial, antidiabetic, estrogenic, anti-inflammatory, antithrombotic, antiviral, neuroprotective, and immunomodulatory properties; therefore, they are currently considered promising candidates in the drug ...
Fabiola De Luca, Carla Di Chio, Maria Zappala', Roberta Ettari   +3 more
openaire   +2 more sources

An orally available non-nucleotide STING agonist with antitumor activity

Science, 2020
Targeting STING for cancer therapy Activation of the STING (stimulator of interferon genes) protein by cyclic dinucleotide metabolites plays a critical role in antitumor immunity.
B. Pan, Samanthi A. Perera, J. Piesvaux, J. Presland, Gottfried K. Schroeder, J. Cumming, B. Trotter, M. Altman, A. Buevich, B. Cash, S. Cemerski, Wonsuk Chang, Yiping Chen, P. Dandliker, Guo Feng, Andrew M Haidle, T. Henderson, James P. Jewell, I. Kariv, Ian Knemeyer, J. Kopinja, Brian M. Lacey, J. Laskey, C. Lesburg, Rui Liang, B. Long, Min Lu, Yanhong Ma, E. Minnihan, Greg O'Donnell, Ryan Otte, Laura Price, L. Rakhilina, B. Sauvagnat, Sharad K Sharma, S. Tyagarajan, Hyun Woo, D. Wyss, Serena Xu, D. J. Bennett, G. Addona   +40 more
semanticscholar   +1 more source

Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic

Science, 2020
Targeting STING for cancer therapy Activation of the STING (stimulator of interferon genes) protein by cyclic dinucleotide metabolites plays a critical role in antitumor immunity.
E. Chin, Chenguang Yu, Vincent F. Vartabedian, Y. Jia, M. Kumar, A. M. Gamo, W. Vernier, Sabrina H. Ali, Mildred Kissai, Daniel C. Lazar, N. Nguyen, Laura E. Pereira, B. Benish, A. Woods, S. Joseph, A. Chu, Kristen A. Johnson, Philipp N. Sander, Francisco Martínez-Peña, Eric N. Hampton, T. Young, D. Wolan, A. Chatterjee, P. Schultz, H. Petrassi, J. Teijaro, L. Lairson   +26 more
semanticscholar   +1 more source